# Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT00581945** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 147 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00581945
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2011-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581945, "Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00581945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*